©The Author(s) 2025.
World J Hepatol. Nov 27, 2025; 17(11): 112573
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.112573
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.112573
Figure 2 Challenges and future directions.
AI: Artificial intelligence; EHRs: Electronic health records; T2DM: Type 2 diabetes mellitus; MASLD: Metabolic dysfunction-associated steatotic liver disease; NAFLD: Non-alcoholic fatty liver disease.
- Citation: Correa TL, Duong N. Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes. World J Hepatol 2025; 17(11): 112573
- URL: https://www.wjgnet.com/1948-5182/full/v17/i11/112573.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i11.112573